Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Foeldvari

Showing results (141-150 of 174) with videos related to

Pageof 18
Sort By:
Arthritis Research & Therapy|April 10, 2024
Anxiety and depression symptoms in adolescents and young adults with juvenile idiopathic arthritis: results of an outpatient screeningFlorian Milatz, Jens Klotsche, Martina Niewerth, et al.
Annals of the Rheumatic Diseases|June 8, 2010
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trialIris Vilca, Pablo Garcia Munitis, Angela Pistorio, et al.
The Journal of Rheumatology|October 13, 2009
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Dinesh Khanna, Oliver Distler, Jerome Avouac, et al.
Arthritis and Rheumatism|February 3, 2007
Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort studySheila Oliveira, Angelo Ravelli, Angela Pistorio, et al.
Rheumatology (Oxford, England)|January 20, 2024
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registryDaniel J Lovell, Nikolay Tzaribachev, Michael Henrickson, et al.
Arthritis Care & Research|June 18, 2023
Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus MeetingsIvan Foeldvari, Kathryn S Torok, Jordi Anton, et al.
Clinical Immunology (Orlando, Fla.)|October 3, 2022
Update of evidence- and consensus-based guidelines for the treatment of juvenile idiopathic arthritis (JIA) by the German Society of Pediatric and Juvenile Rheumatic Diseases (GKJR): New perspectives on interdisciplinary carePrasad T Oommen, Timmy Strauss, Karen Baltruschat, et al.
Rheumatology (Oxford, England)|January 23, 2019
The European network for care of children with paediatric rheumatic diseases: care across bordersPavla Dolezalova, Jordi Anton, Tadej Avcin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 23, 2015
Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven yearsDaniel J Lovell, Nicolino Ruperto, Richard Mouy, et al.
Pediatric Rheumatology Online Journal|October 3, 2019
Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)Ivan Foeldvari, Jens Klotsche, Gabriele Simonini, et al.
Pageof 18

Showing results (141-150 of 174) with videos related to

Sort By:
Pageof 18
Arthritis Research & Therapy|April 10, 2024
Anxiety and depression symptoms in adolescents and young adults with juvenile idiopathic arthritis: results of an outpatient screeningFlorian Milatz, Jens Klotsche, Martina Niewerth, et al.
Annals of the Rheumatic Diseases|June 8, 2010
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trialIris Vilca, Pablo Garcia Munitis, Angela Pistorio, et al.
The Journal of Rheumatology|October 13, 2009
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Dinesh Khanna, Oliver Distler, Jerome Avouac, et al.
Arthritis and Rheumatism|February 3, 2007
Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort studySheila Oliveira, Angelo Ravelli, Angela Pistorio, et al.
Rheumatology (Oxford, England)|January 20, 2024
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registryDaniel J Lovell, Nikolay Tzaribachev, Michael Henrickson, et al.
Arthritis Care & Research|June 18, 2023
Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus MeetingsIvan Foeldvari, Kathryn S Torok, Jordi Anton, et al.
Clinical Immunology (Orlando, Fla.)|October 3, 2022
Update of evidence- and consensus-based guidelines for the treatment of juvenile idiopathic arthritis (JIA) by the German Society of Pediatric and Juvenile Rheumatic Diseases (GKJR): New perspectives on interdisciplinary carePrasad T Oommen, Timmy Strauss, Karen Baltruschat, et al.
Rheumatology (Oxford, England)|January 23, 2019
The European network for care of children with paediatric rheumatic diseases: care across bordersPavla Dolezalova, Jordi Anton, Tadej Avcin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 23, 2015
Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven yearsDaniel J Lovell, Nicolino Ruperto, Richard Mouy, et al.
Pediatric Rheumatology Online Journal|October 3, 2019
Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)Ivan Foeldvari, Jens Klotsche, Gabriele Simonini, et al.
Pageof 18